Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well hu14.18-interleukin-2 (IL2) fusion protein works
when given together with sargramostim and isotretinoin in treating patients with relapsed or
refractory neuroblastoma. Biological therapy, such as hu14.18-IL2 fusion protein, and
sargramostim work in different ways to stimulate the immune system and stop tumor cells from
growing. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving
hu14.18-IL2 fusion protein together with sargramostim and isotretinoin may kill more tumor
cells.